BR0109266A - Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto - Google Patents

Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto

Info

Publication number
BR0109266A
BR0109266A BR0109266-9A BR0109266A BR0109266A BR 0109266 A BR0109266 A BR 0109266A BR 0109266 A BR0109266 A BR 0109266A BR 0109266 A BR0109266 A BR 0109266A
Authority
BR
Brazil
Prior art keywords
compound
cancer
affected mammal
affected
releasing
Prior art date
Application number
BR0109266-9A
Other languages
English (en)
Inventor
Robert A Copeland
Charles F Albright
Andrew P Combs
Radine L Dowling
Nilsa R Graciani
Wei Han
C Anne Higley
Pearl S Huang
Eddy W Yue
Susan V Dimeo
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of BR0109266A publication Critical patent/BR0109266A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO DE TRATAMENTO DE UM MAMìFERO AFETADO COM UM CâNCER, MéTODO DE LIBERAçãO DE UM COMPOSTO NAS CéLULAS DE UM MAMìFERO AFETADO COM UM CâNCER E USO DO COMPOSTO". A presente invenção refere-se a agentes antineoplásticos conjugados a peptídeos cliváveis por enzima que compreendem a seq³ência de reconhecimento de aminoácidos de uma peptidase ligada a membrana e/ou secretada pela célula, e ao uso de tais compostos conjugados como agentes quimioterapêuticos no tratamento alvo de cânceres.
BR0109266-9A 2000-03-15 2001-03-15 Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto BR0109266A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18938700P 2000-03-15 2000-03-15
PCT/US2001/008589 WO2001068145A2 (en) 2000-03-15 2001-03-15 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use

Publications (1)

Publication Number Publication Date
BR0109266A true BR0109266A (pt) 2003-04-29

Family

ID=22697116

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109266-9A BR0109266A (pt) 2000-03-15 2001-03-15 Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto

Country Status (19)

Country Link
US (1) US6844318B2 (pt)
EP (1) EP1263473A2 (pt)
JP (1) JP2003526683A (pt)
KR (1) KR20030009388A (pt)
CN (1) CN1418112A (pt)
AU (2) AU2001245836A1 (pt)
BR (1) BR0109266A (pt)
CA (1) CA2401873A1 (pt)
CZ (1) CZ20022998A3 (pt)
EE (1) EE200200522A (pt)
HU (1) HUP0300590A2 (pt)
IL (1) IL151400A0 (pt)
MX (1) MXPA02009019A (pt)
NO (1) NO20024238D0 (pt)
PL (1) PL360826A1 (pt)
RU (1) RU2002127425A (pt)
SK (1) SK12872002A3 (pt)
TR (1) TR200202183T2 (pt)
WO (1) WO2001068145A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004510702A (ja) * 2000-06-14 2004-04-08 メダレックス，インコーポレイティド イソロイシンを有するプロドラッグ化合物
CA2447023A1 (en) * 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
CA2450316A1 (en) * 2001-06-11 2002-12-19 Medarex, Inc. Cd10-activated prodrug compounds
JP4342314B2 (ja) * 2001-12-17 2009-10-14 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド 病変部位への特異的送達のための開裂薬剤
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
JP4511805B2 (ja) * 2002-04-26 2010-07-28 武田薬品工業株式会社 ネプリライシンの活性測定法
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
FR2851471B1 (fr) * 2003-02-24 2006-07-28 Synt Em Composes comprenant au moins une substance active et au moins un vecteur relies par un agent de liaison, leurs utilisations et lesdits agents de liaison
DE10310082A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
US20100113328A1 (en) * 2003-05-29 2010-05-06 The Scripps Research Institute Targeted delivery to legumain-expressing cells
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
US20050137141A1 (en) * 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
JP4654418B2 (ja) 2004-03-31 2011-03-23 独立行政法人産業技術総合研究所 上皮系細胞増殖促進剤
JP2007099750A (ja) * 2005-02-25 2007-04-19 Hokkaido Univ 腫瘍組織で選択的に分解性を示す血中滞留性素子
WO2006124711A1 (en) * 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
CN101374856A (zh) * 2005-11-29 2009-02-25 斯克里普斯研究学院 抑制肿瘤细胞浸润、转移和血管生成
AU2007315790A1 (en) * 2006-06-30 2008-05-08 Interface Biologics, Inc. Bioresponsive polymers
EP1977765A1 (en) * 2007-04-03 2008-10-08 Diatos Peptide prodrugs
GB0707034D0 (en) * 2007-04-12 2007-05-23 St Andrews The Compounds
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
ITUD20130024A1 (it) 2013-02-22 2014-08-23 Carlo Galli Aptameri per la realizzazione di dispositivi biomedicali impiantabili in tessuto e relativo metodo
WO2014145242A1 (en) * 2013-03-15 2014-09-18 The Board Of Trustees Of The University Of Illinois Peptide-coated polymer carriers
GB2516882A (en) 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
JP6353052B2 (ja) * 2013-08-26 2018-07-04 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． ＥｒｂＢ２陽性癌の予防及び／又は治療のための方法
CA2958568A1 (en) 2014-08-20 2016-02-25 Health Research, Inc. Methods for prophylaxis and/or treatment of erbb1 positive cancers
EP2995612A1 (en) * 2014-09-12 2016-03-16 Université de Strasbourg Novel non-natural amino acids, their process of preparation and uses thereof
TW201920234A (zh) 2017-09-11 2019-06-01 美商領導醫療有限公司 類鴉片促效劑肽及其用途
KR20230129455A (ko) 2020-12-21 2023-09-08 코넬 유니버시티 펩타이드-연결된 약물 전달 시스템
CA3203072A1 (en) 2020-12-22 2022-06-30 Andrea CASAZZA Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety
CN113876968B (zh) * 2021-10-29 2023-06-09 上海市第一人民医院 Mmp9响应的t1/t2切换型mr纳米探针及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4466919A (en) * 1982-12-16 1984-08-21 Monsanto Company Peptide substrates for mammalian collagenase
FR2546163B1 (fr) 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US6143864A (en) 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
SI0769967T1 (sl) * 1994-08-19 2008-06-30 Wallone Region Konjugati vsebujoäśi protitumorna sredstva in njihova uporaba
JP2000506494A (ja) 1995-10-18 2000-05-30 メルク エンド カンパニー インコーポレーテッド 良性前立腺過形成の治療に有用な複合体
WO1997048725A1 (en) 1996-06-21 1997-12-24 Peptech Limited Novel peptides for prevention and treatment of infection
WO1998010795A2 (en) 1996-09-10 1998-03-19 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
CA2265476A1 (en) 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DE69723473T2 (de) 1996-10-15 2004-05-27 The Liposome Co., Inc. Peptid-lipid konjugate, liposomen und liposomale arzneimittelverabreichung
HRP970566A2 (en) 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
WO1998046250A1 (en) 1997-04-14 1998-10-22 The Regents Of The University Of California Peptide antiestrogen compositions and methods for treating breast cancer
WO1999002175A1 (en) * 1997-07-10 1999-01-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
AU773420B2 (en) 1998-12-11 2004-05-27 Medarex, Inc. Prodrug compounds and process for preparation thereof
WO2000059930A1 (en) 1999-04-05 2000-10-12 Merck & Co., Inc. A method of treating cancer
EP1176985A2 (en) 1999-04-28 2002-02-06 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
JP2002544242A (ja) * 1999-05-14 2002-12-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 酵素活性化抗腫瘍プロドラッグ化合物

Also Published As

Publication number Publication date
WO2001068145A3 (en) 2002-07-11
CZ20022998A3 (cs) 2003-05-14
CA2401873A1 (en) 2001-09-20
IL151400A0 (en) 2003-04-10
KR20030009388A (ko) 2003-01-29
MXPA02009019A (es) 2003-02-12
CN1418112A (zh) 2003-05-14
US20020103133A1 (en) 2002-08-01
EP1263473A2 (en) 2002-12-11
HUP0300590A2 (hu) 2003-07-28
US6844318B2 (en) 2005-01-18
RU2002127425A (ru) 2004-03-27
AU2001245836A1 (en) 2002-07-16
AU4583601A (en) 2001-09-24
WO2001068145A2 (en) 2001-09-20
JP2003526683A (ja) 2003-09-09
SK12872002A3 (sk) 2003-05-02
PL360826A1 (en) 2004-09-20
EE200200522A (et) 2004-04-15
NO20024238D0 (no) 2002-09-05
TR200202183T2 (tr) 2007-01-22

Similar Documents

Publication Publication Date Title
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
BR9910251A (pt) Estimulação hematopoiética
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
ATE136792T1 (de) Zellmembran-mischungsmittel enthaltende molekularkonjugate
BR0107643A (pt) Composições e processos para a terapia e diagnóstico de c ncer de próstata
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
CY1113370T1 (el) Ενεσιμο φαρμακευτικο σκευασμα αποτελουμενο απο ενα κυτταροστατικο και μια μηλεϊνιμιδο ομαδα συνδεομενη δια ενος παρεμβαλλομενου μοριου
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
BR0108930A (pt) Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente
BR0013081A (pt) Pirimidino-2,4,6-trionas inibidoras de metaloproteinases
ATE344801T1 (de) Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
PT1075282E (pt) Conjugados analogos de peg-lhrh
ES2249888T3 (es) Conjugados de paclitaxel solubles en agua, combinados con irradiacion para el tratamiento del cancer.
TR200002299T2 (tr) Epotilon kompozisyonları.
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
BR9712589A (pt) Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica.
MY138883A (en) Use of asiatic acid for treatment of cencer
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 7/06 (2006.01), A61K 47/65 (2017.01), A61K 38